Laure Peyro‐Saint‐Paul

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul et al. · EClinicalMedicine · 2021 · 64 citations · Full text

Risk and Cost Associated With Drug–Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France

Ludivine Demessine, Laure Peyro‐Saint‐Paul, Edward M. Gardner et al. · Open Forum Infectious Diseases · 2019 · 51 citations · Full text

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study

F. Mouriaux, Vincent Servois, J J Parienti et al. · British Journal of Cancer · 2016 · 47 citations · Full text

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study

Laure Peyro‐Saint‐Paul, Christian Créveuil, Olivier Heinzlef et al. · Journal of the Neurological Sciences · 2016 · 46 citations

Cognitive Rehabilitation, Neurological Disorder, Medicine +8

Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis

Charles Dolladille, Basile Chrétien, Laure Peyro‐Saint‐Paul et al. · Neurotherapeutics · 2021 · 35 citations · Full text

Therapeutic Drug Monitoring, Oncology, Medicine +6